Hemostemix Inc
🇨🇦XTSX.HEMCanadaHealthcare
PriceCA$0.060.00 (0%)
Latest anomalies
Negative 1 detected in the last 120 days
- High: 0
- Medium: 3
- Low: 0
Overnight gap: a gap down from the prior close
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA4236943060
- CUSIP
- 423694306
Company
- Employees
- 0
- Headquarters
- Calgary, Canada
- Website
- https://hemostemix.com
Market
- Shares outstanding
- 181.1M
- Market cap
- CA$10.86M
Highlights
No high and low reported for today's session.
- Market cap
- CA$10.86M
- EPS LTM
- -CA$0.02calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -3.38calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$3.21M-66.02%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$2.31M-545.92%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Hemostemix Inc is a company in the healthcare sector, listed on TSX Venture Exchange (Canada) under the ticker HEM. Its market capitalisation is CA$10.86M, from 181.1M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CA$0.04 and CA$0.13, and the last close of CA$0.06 sits 22% of the way up that range. The company is headquartered in Calgary, Canada.
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.